Results 211 to 220 of about 1,333,101 (244)

IL-17 and IL-23 inhibitors dose spacing in adult psoriatic patients: a real-world pilot study. [PDF]

J Dtsch Dermatol Ges
Mastorino L, Dapavo P, Ortoncelli M, Bongiovanni E, Quaglino P, Ribero S.   +5 more
europepmc   +1 more source

MASLD and liver fibrosis in patients with psoriasis receiving IL-17 or IL-23 inhibitors: a systematic review. [PDF]

Ther Adv Gastroenterol
González Fernández J, Prieto-Torres L, Ara Martín M, Martínez-Domínguez SJ.   +3 more
europepmc   +1 more source

IL-23 Promotes γδT Cell Activity in Dry Eye Disease Progression. [PDF]

Invest Ophthalmol Vis Sci
Li Y, Luo Z, Liu Z, Zhu X, Reinach PS, Li L, Chen W.   +6 more
europepmc   +1 more source

HPV16 E6 and E7 expressing cancer cells suppress the antitumor immune response by upregulating KLF2-mediated IL-23 expression in macrophages. [PDF]

J Immunother Cancer
Prins R, Fernandez DJ, Akbari O, Da Silva DM, Kast WM.   +4 more
europepmc   +1 more source

Correction for Ota et al., Engineering a protease-stable, oral single-domain antibody to inhibit IL-23 signaling. [PDF]

Proc Natl Acad Sci U S A
europepmc   +1 more source

Correction: HPV16 E6 and E7 expressing cancer cells suppress the antitumor immune response by upregulating KLF2-mediated IL-23 expression in macrophages. [PDF]

J Immunother Cancer
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Biologics update: IL‐23 inhibitors

Dermatological Reviews, 2021
AbstractIntroductionIL‐23 inhibitors have shown long‐term efficacy and safety for the treatment of moderate‐to‐severe plaque psoriasis in adults. Guselkumab has also been approved to treat psoriatic arthritis while tildrakizumab and risankizumab are currently under investigation for treating psoriatic arthritis.
Julie Hong, Edward Hadeler, Megan Mosca, Mimi Chung, Samuel Yeroushalmi, Marwa Hakimi, Wilson Liao, Tina Bhutani   +7 more
openaire   +1 more source

IL-23 and the Tumor Microenvironment

2021
The tumor microenvironment (TME), which assists in the development, progression, and metastasis of malignant cells, is instrumental in virtually every step of tumor development. While a healthy TME can protect against malignancy, in an unhealthy state, it can result in aberrant cellular behavior and augment tumor progression.
Sweta, Subhadarshani, Nabiha, Yusuf, Craig A, Elmets   +2 more
openaire   +2 more sources

Targeting IL-23 in Crohn’s disease

Expert Review of Clinical Immunology, 2018
Interleukin (IL)-23, a cytokine produced by antigen presenting cells, targets both T cells and non-T cell types with the downstream effect of enhancing inflammatory pathways. Genome-wide association studies and data from human and mouse models of intestinal inflammation support the pathogenic role of IL-23 in Crohn's disease (CD), an immune-mediated ...
Silvia, Sedda, Gerolamo, Bevivino, Giovanni, Monteleone   +2 more
openaire   +2 more sources

Targeting IL-23 in human diseases

Expert Opinion on Therapeutic Targets, 2010
IL-23 is one of the most intriguing cytokine for its many immunological functions, which are the basis of its important role in host defense but also of its possible contribution to the pathogenesis of several diseases.The literature and patents about IL-23 pathway and their targeting in therapeutic potential applications. Findings published within the
D'ELIOS, MARIO MILCO, DEL PRETE, GIANFRANCO, AMEDEI, AMEDEO   +2 more
openaire   +4 more sources